Head-to-head · WeighScore
LevelsRx vs TeleHealth Med
By GLP-1 ScorecardUpdated
Score comparison
LevelsRx has the higher recorded score — 66.6/100 to 66.1/100, but only just.
LevelsRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. LevelsRx is a US direct-to-consumer telehealth offering compounded GLP-1 weight-loss medication, including compounded semaglutide (injectable and an oral liposomal liquid) starting at 150 dollars per month and compounded tirzepatide starting at 240 dollars per month, plus Sermorelin. TeleHealth Med is close behind and may still be the better fit — see the factor split below.
Before you choose
Before comparing the headline prices, the LevelsRx review and the TeleHealth Med review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, LevelsRx vs TelePeptide and REMEVi vs TeleHealth Med compare each of them with another graded program, and the list of alternatives to LevelsRx ranks the programs closest to LevelsRx on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the System Labs review covers one graded close to these two, at 68.4/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | LevelsRx | TeleHealth Med |
|---|---|---|
| WeighScore | 66.6/100 | 66.1/100 |
| Grade | C | C |
| Site position | #201 | #222 |
| Semaglutide | $150/mo (starting dose, compounded) | $147/mo (starting dose, compounded) |
| Tirzepatide | $240/mo (starting dose, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Strengths
- Both injectable and oral semaglutide plus tirzepatide, with same-day virtual visits
- Weight-loss money-back warranty if targets are not met
- 24-7 phone and email support with unlimited online provider visits
What to consider
- Compounding pharmacy is not named publicly
- States served are not published on the site
- Prices are 'starting at' figures that may rise with dose
Strengths
- Corporate entity disclosed (TeleHealth Med, Inc.) — clearer accountability than undisclosed competitors
- Publishes the FDA compounded-medication disclaimer
- 503A pharmacy designation stated in the FAQ
- Honest disclosure that testimonials are compensated and results aren't independently verified
- Both injectable and sublingual forms offered
What to consider
- Specific 503A pharmacy partner not named
- LegitScript ID number not shown in text — only a verification link
- Full states-served list not disclosed
- Named medical director not disclosed
- Dose tiers beyond the $147/mo starting price not published
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.